Chemaphor Inc.
TSX VENTURE : CFR

Chemaphor Inc.

November 19, 2010 08:00 ET

RETRANSMISSION: Chemaphor Announces Official Launch of Avivagen Animal Health Inc.

OTTAWA, ONTARIO--(Marketwire - Nov. 19, 2010) - Chemaphor Inc. (TSX VENTURE:CFR) and its subsidiary Avivagen Animal Health Inc, today announced that Avivagen Animal Health has officially launched its commercial operations this week. Avivagen has begun marketing exclusively through the veterinary channel in Canada its proprietary Oximunol™ Chewable Tablets for dogs and its in-licensed VetStem RC regenerative cell treatment for dogs, horses and cats.

Dave Hankinson, CEO of Chemaphor and Avivagen commented that "it is gratifying that Chemaphor, through Avivagen, is now able to enter the market with its first commercial products, which have come to fruition after much effort expended on both the research and development and the business development fronts. Our sales representatives are finding considerable interest and excitement across Canada among the veterinarians they visit, for both the VetStem RC regenerative cell treatment and Oximunol™ Chewable Tablets. Indeed, I am pleased to say that the first orders already have been received by Avivagen, and that delivery is slated to begin shortly."

At the same time, Chemaphor has launched a dedicated, interactive website in support of Avivagen's products and services (www.avivagen.com). Dave Hankinson remarked that "we believe it is important to take full advantage of the social media capabilities of online communities, to communicate with and build the all-important, long-term relationships with pet parents and veterinarians. At the same time this discussion creates awareness of and buying interest in our novel and innovative products and services. Accordingly, we have appointed a dedicated consumer and marketing communications coordinator, Jennifer Febel, who will be blogging on the website and facilitating discussion with website visitors through services such as Facebook and Twitter, as well as by regular email. Veterinarians who would like to discuss aspects of our products and services, can contact Dr. Isabelle Epshtein-Verzberger, our veterinary research scientist, whose responsibilities include leading the canine clinical trials program. Questions of a general nature can be directed to the appropriate individual though the Avivagen customer service support desk."

For further information please direct enquiries to any of the appropriate resources listed below.

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products to humans and animals to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various, potential human applications. More information can be found at www.chemaphor.com.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with Chemaphor's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Chemaphor or its management. The forward-looking statements are not historical facts, but reflect Chemaphor's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information